Alchemab Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
60
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$33.3M
- Investors
-
13
Alchemab Therapeutics General Information
Description
Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach. The company's antibodies are found through an unbiased and function-first approach using three complementary processes and technologies, enabling patients to control the power of naturally protective antibodies and get themselves treated.
Contact Information
Website
www.alchemab.comCorporate Office
- East Side, Office 1.02
- Kings Cross
- London N1C 4AX
- England, United Kingdom
Corporate Office
- East Side, Office 1.02
- Kings Cross
- London N1C 4AX
- England, United Kingdom
Alchemab Therapeutics Timeline
Alchemab Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series A) | 09-Jul-2026 | $33.3M | Completed | Clinical Trials - Phase 1 | ||
| 9. Later Stage VC | 03-Jul-2025 | Completed | Clinical Trials - Phase 1 | |||
| 8. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 7. Grant | 06-Jun-2024 | Completed | Clinical Trials - Phase 1 | |||
| 6. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 5. Early Stage VC (Series A3) | 21-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 05-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 23-Jun-2020 | $224K | $224K | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 01-Jan-2019 | Completed | Startup |
Alchemab Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 Preferred | ||||||||
| Series A-3 Preferred | ||||||||
| Series A-2 Preferred | ||||||||
| Series A Preferred | 12,000,000 | $0.000133 | $0.67 | $0.67 | 1x | $0.67 | 12.58% | |
| Series A Preferred | 41,844,247 | $0.000133 | $1.72 | $1.72 | 1x | $1.72 | 43.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Alchemab Therapeutics Comparisons
Industry
Financing
Details
Alchemab Therapeutics Competitors (8)
One of Alchemab Therapeutics’s 8 competitors is STORM Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| STORM Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| NRG Therapeutics | Venture Capital-Backed | Stevenage, United Kingdom | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Aquinnah | Venture Capital-Backed | Cambridge, MA | ||||
| Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
Alchemab Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alchemab Therapeutics Patents
Alchemab Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026139720-A2 | Anti-pgdh antibodies | Pending | 20-Dec-2024 | ||
| WO-2026139720-A3 | Anti-pgdh antibodies | Pending | 20-Dec-2024 | ||
| US-20260103516-A1 | Anti-unc5c antibodies | Pending | 10-Oct-2024 | ||
| GB-202413525-D0 | Antibodies | Inactive | 10-Sep-2024 | ||
| GB-202410982-D0 | Antibodies | Inactive | 26-Jul-2024 |
Alchemab Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alchemab Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Business Bank | Lender/Debt Provider | Minority | ||
| DCVC | Venture Capital | Minority | ||
| DHVC | Venture Capital | Minority | ||
| Lightstone Ventures | Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority |
Alchemab Therapeutics FAQs
-
When was Alchemab Therapeutics founded?
Alchemab Therapeutics was founded in 2019.
-
Where is Alchemab Therapeutics headquartered?
Alchemab Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Alchemab Therapeutics?
Alchemab Therapeutics has 60 total employees.
-
What industry is Alchemab Therapeutics in?
Alchemab Therapeutics’s primary industry is Drug Discovery.
-
Is Alchemab Therapeutics a private or public company?
Alchemab Therapeutics is a Private company.
-
What is the current valuation of Alchemab Therapeutics?
The current valuation of Alchemab Therapeutics is .
-
What is Alchemab Therapeutics’s current revenue?
The current revenue for Alchemab Therapeutics is .
-
How much funding has Alchemab Therapeutics raised over time?
Alchemab Therapeutics has raised $66.3M.
-
Who are Alchemab Therapeutics’s investors?
British Business Bank, DCVC, DHVC, Lightstone Ventures, and Lilly USA are 5 of 13 investors who have invested in Alchemab Therapeutics.
-
Who are Alchemab Therapeutics’s competitors?
STORM Therapeutics, NRG Therapeutics, Adaptimmune Therapeutics, Aquinnah, and Mission Therapeutics are some of the 8 competitors of Alchemab Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
